Valeant Pharmaceuticals Completes Amended Credit Facility
Date: 09/11/12
Cahill represented the administrative agent in connection with the $175,000,000 incremental revolving loan credit facility for Valeant Pharmaceuticals International, Inc. The loan will be added to Valeant’s existing $3,800,000 billion facility, comprised of a $1,225,000,000 initial draw term loan, a $275,000,000 revolving credit facility, a $500,000,000 delayed draw term loan facility, a $500,000,000 series A new term loan facility, and a $1,300,000,000 trance B term loan facility.